- Home
- NRSN vs HBIO Comparison
NRSN vs HBIO Comparison
Compare NRSN & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- HBIO
- Stock Information
- Founded
- NRSN 2017
- HBIO 1901
- Country
- NRSN Israel
- HBIO United States
- Employees
- NRSN N/A
- HBIO N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- NRSN Health Care
- HBIO Industrials
- Exchange
- NRSN Nasdaq
- HBIO Nasdaq
- Market Cap
- NRSN 26.0M
- HBIO 24.6M
- IPO Year
- NRSN 2021
- HBIO 2000
- Fundamental
- Price
- NRSN $1.18
- HBIO $0.47
- Analyst Decision
- NRSN Buy
- HBIO Buy
- Analyst Count
- NRSN 2
- HBIO 3
- Target Price
- NRSN $14.00
- HBIO $2.50
- AVG Volume (30 Days)
- NRSN 1.4M
- HBIO 1.1M
- Earning Date
- NRSN 09-17-2025
- HBIO 11-06-2025
- Dividend Yield
- NRSN N/A
- HBIO N/A
- EPS Growth
- NRSN N/A
- HBIO N/A
- EPS
- NRSN N/A
- HBIO N/A
- Revenue
- NRSN N/A
- HBIO $88,750,000.00
- Revenue This Year
- NRSN N/A
- HBIO N/A
- Revenue Next Year
- NRSN N/A
- HBIO $7.13
- P/E Ratio
- NRSN N/A
- HBIO N/A
- Revenue Growth
- NRSN N/A
- HBIO N/A
- 52 Week Low
- NRSN $0.80
- HBIO $0.28
- 52 Week High
- NRSN $2.60
- HBIO $3.04
- Technical
- Relative Strength Index (RSI)
- NRSN 46.42
- HBIO 48.15
- Support Level
- NRSN $1.14
- HBIO $0.42
- Resistance Level
- NRSN $1.28
- HBIO $0.56
- Average True Range (ATR)
- NRSN 0.15
- HBIO 0.03
- MACD
- NRSN 0.03
- HBIO -0.00
- Stochastic Oscillator
- NRSN 22.33
- HBIO 33.00
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.